Weihrauch in der Therapie von hirneigenen Tumoren und Hirnödemen

Zusammenfassung

Das Harz des Weihrauchbaums enthält therapeutisch wirksame Boswelliasäuren (BA), die selektiv die Leukotriensynthese hemmen. Dadurch wird die Entzündungskaskade ohne nennenswerte Nebenwirkungen unterbrochen. Auch bei Langzeiteinnahme von Weihrauch bleibt die Initialwirkung erhalten. Indikationen für eine Therapie mit Weihrauch sind alle chronisch-entzündlichen und allergischen Erkrankungen. Die komplementäre Onkologie ist ein möglicher Einsatzbereich. Forschungsergebnisse zeigen, dass BA Topoisomerasen hemmen und somit die Apoptose von malignen Zellen einleiten.

Summary

The resin of the frankincense tree contains therapeutically effective boswellic acids (BA). Four predominant BA selectively inhibit the synthesis of Leucotrienes (LT). A variety of chronic diseases is predominantly accompanied by excessive formation of LT and hence support and prolong the inflammatory process. Starting from the arachidonic acid, the inflammatory and pain cascade is interrupted without significant side effects. Even on the basis of long-term intake, the initial effects are maintained. Indications for a frankincense therapy are all chronic inflammatory and allergic diseases. A different pathway of activity involves the Inhibition of topoisomerases I and II via frankincense. In vitro studies show that at higher concentrations BA inhibited the proliferation of tumour cells, possibly by inducing programmed cell death (apoptosis) of malignant cells. The frankincense genus from northeast Africa (Boswellia carterii), in particular Eritrea, delivers an outstanding quality of the pharmaceutical drug and is free from heavy metals and preservatives. Based on clinical experience, the treatment of patients having tumor induced oedema derived from brain tumors (astrocytoma, glioblastoma) and brain metastases with frankincense (boscari®), have revealed impressive results. At higher concentrations (3 × 4 - 5 cps.) the effectiveness of anti-oedemic acrtivity and complience is observed. Peri-tumoural brain oedemas are generally suppressed employing glucocorticosteroides that can cause substantial side effects lead to further chronic illnesses especially after long-term application.

Schlüsselwörter

Hirntumor - Hirnödem - Leukotriene - Topoisomerase - Weihrauch - Boswelliasäuren

Keywords

brain tumor - brain oedema - leucotrienes - topoisomerases - frankincense - incense - boswellic acids

Literatur

• 01 Ammon HZ P, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids.  J Ethnopharmacol. 1993;  38 113-119
• 02 Boden S E, Schweizer S, Bertsche T. Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid.  Molecular Pharmacology. 2001;  60 267-273
• 03 Böker D K, Winking M. Die Rolle von Boswelliasäuren in der Therapie maligner Gliome.  Deutsches Ärzteblatt. 1997;  94 1197-1199
• 04 Burden D A, Osheroff N. Mechanism of action of eucaryotic topoisomerase II and drugs targeted to the enzyme.  Biochim Biophys. 1998;  1400 139-154
• 05 Capranico G, Binaschi M, Borgnetto M E, Zunino F, Palumbo M. A protein mediated mechanism for the DNA sequence specific action of topoisomerase II poisons.  Trends in Pharmacological Sciences. 1997;  18 323-329
• 06 el-Khadem H, el-Shafei Z M, el-Sekeily A, Rahman M M. Derivatives of boswellic acids.  Planta Med. 1972;  22 157-9
• 07 Ferguson L R, Baguley B C. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes.  Mutation Research. 1996;  355 91-101
• 08 Glaser T, Winter S, Groscurth P, Safayhi H, Sailer E R, Ammon H P T, Schabet M, Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity.  British Journal of Cancer. 1999;  80 756-765
• 09 Gupta I, Gupta V, Parihar A, Gupta S, Lüdtke R, Safayhi H, Ammon H P T. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study.  European Journal of Medical Research. 1998;  3 511-514
• 10 Gupta I, Parihar A, Malhotra P, Singh G B, Lüdtke R, Safayhi H, Ammon H P T. Effects of Boswellia serrata gum resin in patients with ulcerative colitis.  European Journal of Medical Research. 1997;  2 37-43
• 11 Heldt R M, Syrovets T, Winking M. Boswellic acids exhibit cytotoxic effects on brain tumor cells independent from 5-lipoxygenase Inhibition. Naunyn Schmiedeberg's Archive of Pharmacology 1997 355 Abstr. 30
• 12 Hoernlein R, Ammon H P T. et al . AKBA induces apoptosis in HL60 and CCRF-CEM cells and inhibits topoisomerase I.  J Pharmacol Exp Ther. 1999;  288 613-619
• 13 Huan M T, Badmaev V, Ding Y, Liu Y, Xie J G, Ho C T. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta- boswellic acid.  Biofactors. 2000;  13 225-230
• 14 Janssen G, Bode U, Breu H, Dohrn B, Engelbrecht V, Göbel U. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors.  Klinische Pädiatrie. 2000;  212 189-195
• 15 Jazwinski S M, Edelman G M. Evidence for participation of a multiprotein complex in yeast DNA replication in vitro.  The Journal of Biological Chemistry. 1984;  259 6852-6857
• 16 Jing Y, Xia L, Han R. Growth inhibition and differentiation of promyelocytic cells (HL-60) induced by BC-4, an active principle from Boswellia carterii Birdw.  Chinese Medical Sciences Journal. 1992;  7 12-15
• 17 Lewis R A, Austem K F. The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology.  J Clin Invest. 1984;  73 889-897
• 18 Liu J J, Duan R D. et al . Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HAT-29 cells.  Carcinogenesis. 2002;  23 2087-2093
• 19 Mattern M R, Paone R F, Day R S. Eukaryotic DNA repair is blocked at different steps by inhibitors of DNA topoisomerases and of DNA polymerases alpha and beta.  Biochimica et Biophysica Acta. 1982;  697 6-13
• 20 Osherhoff N. Eukaryotic Topoisomerase II - Characterization of enzyme turnover.  The Journal of Biological Chemistry. 1986;  261 9944-9950
• 21 Pardhy R S, a. B,  S C. β-Boswellic acid, acetyl-β-boswellic acid, acetyl-11-keto-β-boswellic acid & 11-keto-β-boswellic acid, four pentacyclic triterpene acids from the resin of Boswellia serrata Roxb.  Indian Journal of Chemistry. 1978;  16B 176-178
• 22 Park Y S, Safayhi H, Golobic M. et al . Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2.  Adv Exp Med Biol. 2002;  507 387-393
• 23 Rahmanian-Schwarz A. Untersuchung zur Wirkung von Boswelliasäuren auf die Überlebenszeit von Ratten mit C6-Gliomen [Dissertation]. Gießen; Universität Gießen 2006
• 24 Safayhi H, Mack T, Sabieraj J, Anazodo M I, Subramanian L R, Ammon H P T. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.  The Journal of Pharmacology and Experimental Therapeutics.. 1992;  261 1143-1146
• 25 Safayhi H, Sailer E R, Ammon H P T. 5-Lipoxygenase inhibition by acetyl-11-keto-boswellic acid (AKBA) by a novel mechanism. Phytomedicine.  1996;  3 71-72
• 26 Safayhi H, Sailer E R, Ammon H P T. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid.  Molecular Pharmacology. 1995;  47 1212-1216
• 27 Sander O, Herborn G, Rau R. Ist H 15 (Harzextrakt von Boswellia Serrata, „Weihrauch”) eine sinnvolle Ergänzung zur etablierten medikamentösen Therapie der chronischen Polyarthritis? Ergebnisse einer doppelblinden Pilotstudie.  Zeitschrift für Rheumatologie. 1998;  57 11-16
• 28 Sehested M, Jensen P B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.  Biochemical Pharmacology. 1996;  51 879-886
• 29 Shao Y, Ho C T, Chin C K, Badmaev V, Ma W, Huang M T. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture.  Planta Med. 1998;  64 328-31
• 30 Shao Y, Huang M T. et al . Inhibitory activity of boswellic acid from Boswellia serrata against human leukemia HL60 cells in culture.  Planta Medica. 1998;  64 328-331
• 31 Simmet T, Luc W, Delank W K, Peskar B A. Biosynthesis of cysteinyl-leukotrienes by human brain tissue in vitro.  Adv Prostaglandin Thromboxane Leukot Res. 1989;  19 402-6
• 32 Wang J. DNA Topoisomerases.  Annual Review of Biochemistry. 1996;  65 635-692
• 33 Winking M. et al .Boswellic acids fail to inhibit tumour growth in malignant glioma treatment. Abstract 55 Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC) Köln; 25. - 28..04..2004
• 34 Winking M, Müller H W, Deinsberger W, Jödicke 'A, Böker D K. Levels of immunoreactive Cysteinyl-Leukotrienes in CSF after subarachnoid haemorrhage correlate with blood flow-velocity in TCD.  Acta Neurochirurgica. 1997;  139 764-769
• 35 Winking M, Sarikaya S, Rahmanian A, Jödicke A, Böker D K. Boswellic acids inhibit glioma growth: a new treatment option?.  Journal of Neuro-Oncology. 2000;  46 97-103
• 36 Winking M, Simmet T. Cysteinyl-leukotrienes production by human astrocytomas in vivo correlates with the malignancy grade and the perifocal edema. In: Nigam S, Honn K, Marnett L: Eicosanoids and other bioactive lipids in cancer, inflamation and radiation injury. Boston - Dordrecht - London; Kluwer Academic publishers 1992 28
• 37 Zirbel  R, Fernando R C, Tuschen-Bürger E, Sahinbas H. Afrikanischer Weihrauch, Boswellia carterii. Erfahrungsheilkunde.  2004;  53 356-363

Korrespondenzadresse